Registration for a live webinar on 'Chronic inflammation, immune cell trafficking and anti-trafficking agents' is now open.See webinar details
Arylamine N-acetyltransferases 1
A selection of talks on Cardiovascular & Metabolic
Anticoagulation for venous thromboembolism
- Dr. Allyson Pishko
- University of Pennsylvania, USA
Pathophysiology and treatment of congestive heart failure in dogs and cats
- Prof. Jessica Ward
- Iowa State University, USA
Genome scans for hypertension
- Prof. Patricia Munroe
- Queen Mary's School of Medicine and Dentistry, UK
Arylamine N-acetyltransferases, I'm Edith Sim. I'm going to be talking about a family of drug metabolizing enzymes. And I have been working on this family of enzymes for more than 20 years. And this represents an update on what was presented previously in a former version of a Henry Stewart talk.
As a code, slides with an "S" in the upper left hand corner contain advanced supplementary information in addition to the core material which is presented throughout the talk.
Arylamine N-acetyltransferases are cytosolic enzymes which are commonly called phase II drug metabolizing enzymes. They're around 30-34 kDa in size, and are widespread amongst eukaryotes and prokaryotes. They were first recognized for their role in the N-acetylation of hydrazines and arylamines.
At the end of the first edition of the Henry Stewart talk, I suggested that the future would be the 3D structure of NAT from mammals, and the effects of mutation on activity. And I ask the question: "Whether NAT has a rule in addition to drug metabolizing enzymatic activity?" In this talk, next, I'm going to identify to what extent the future is here. And the answer is that most of these future ideas will be covered in the current talk. The overview of the talk that I am going to give today is: